Global Partners SillaJen, Transgene and Lee’s Pharmaceutical Confirm Clinical Development Plan for Pexa-Vec

Enrollment of Phase 3 study in first-line advanced liver cancer expected to begin by mid-2015 – To initiate several additional Phase 1/2 trials during 2014 Marchc 26, 2014 Transgene SA, Lee’s Pharmaceutical and SillaJen today unveiled their late-stage clinical development plan for Pexa-Vec oncolytic immunotherapy. The companies plan to initiate a global Phase 3 study in the first-line treatment of advanced …